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To develop and evaluate new therapeutic strategies for the treatment of human cancers, well-characterised preclinical model
systems are a prerequisite. To this aim, we have established xenotransplantation mouse models and corresponding cell cultures
from surgically obtained secondary human liver tumours. Established xenograft tumours were patho- and immunohistologically
characterised, and expression levels of cancer-relevant genes were quantiﬁed in paired original and xenograft tumours
and the derivative cell cultures applying RT-PCR-based array technology. Most of the characteristic morphological and
immunohistochemical features of the original tumours were shown to be maintained. No diﬀerences were found concerning
expression of genes involved in cell cycle regulation and oncogenesis. Interestingly, cytokine and matrix metalloproteinase
encoding genes appeared to be expressed diﬀerentially. Thus, the established models are closely reﬂecting pathohistological and
molecular characteristics of the selected human tumours and may therefore provide useful tools for preclinical analyses of new
antitumour strategies in vivo.
Copyright © 2009 Daniela Mischek et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
The liver is a common site of distant metastasis originating
from diﬀerent neoplasms including gastrointestinal (pan-
creatic, stomach, colorectal), lung and breast cancers. Also
primary liver tumours such as cholangiocellular carcinomas
(CCC), cancers of the bile ducts [1], may disseminate into
the liver. Surgical resection still is the most promising
therapyofsecondarylivertumours,however,onlyaminority
of patients are candidates for resection, and no adjuvant
treatmenthasbeendemonstratedtobeeﬀectiveinincreasing
the survival rate following radical surgery [2, 3]. For
unresectable disease, several treatments have been tested in
the clinical setting; however, none of them can be currently
consideredastandardapproach.Thisalsoappliestosystemic
chemotherapy, although newer regimens appear to at least
improve median survival [4]. Locoregional therapies such
as hepatic intra-arterial chemotherapy and isolated hepatic
perfusion may be oﬀered to patients with unresectable liver
metastases in the absence of extrahepatic disease; however,2 Journal of Biomedicine and Biotechnology
theeﬃcacyofthesetreatmentsisstillbeingdetermined.Both
systemic and locoregional chemotherapy might be useful in
the neoadjuvant setting to increase the resectability of liver
metastases initially not amenable to surgical resection.
Due to its poor prognosis and unsatisfying treatment
options, suitable animal models for secondary liver can-
cer are required as a prerequisite for studying factors
involved in the pathogenesis of the disease as well as
for the development and evaluation of new anticancer
therapies. Various approaches include the use of transgenic
or knockout mice [5, 6] or mouse models, in which
tumour formation is induced chemically [7]. Albeit tumours
develop in all of these mouse models, tumour formation
and progression in mice greatly diﬀer from that in man
[8, 9] due to physiological diﬀerences between the species
and diﬀerences in cellular and molecular events contributing
to cancer development. Tumour models established with
primary human tumour tissue may overcome some of these
limitations. To this aim, immune compromised animals,
such as severe combined immunodeﬁcient (SCID) mice,
are grafted either subcutaneously or orthotopically with
cultured cells [10, 11]o rt i s s u ed e r i v e df r o mh u m a nt u m o u r
material[12–15]providingconvenientmodelsforevaluation
of distinct anticancer strategies, especially those targeting
tumour growth. Although discussions are ongoing arguing
that the orthotopic transplantation model closer resembles
the situation in the patient, subcutaneous xenografts still
remain the standard for cancer drug screening in the phar-
maceutical industry. In both cases, only detailed knowledge
about the transplanted tumour cells will facilitate correct
interpretation of gained results.
Thus, in the present study liver metastases derived from
various human adenocarcinomas were used to establish sub-
cutaneous xenograft tumours in SCID/beige mice. Extensive
histological analyses were performed to demonstrate that the
transplants widely reﬂect the characteristics of the parental
lesion. In addition, gene expression proﬁling by means
of RT-PCR-based microarrays revealed that expression of
cancer-related genes appeared to be similar in corresponding
original and xenograft tumours as well as in derived cell
cultures. Therefore, we conclude that the established tumour
models and cell cultures may represent valuable tools for
the development and analysis of new treatments targeting
secondary liver tumours.
2.MaterialsandMethods
2.1. Human Tumour Tissue. Primary and secondary liver
tumours were obtained from patients at the time of
liver transplantation or surgical resection of the neoplasm.
Immediately after surgical resection, tumour samples were
transferred into transport medium (RPMI 1640, Sigma-
Aldrich, Wien, Austria) containing 10% heat-inactivated
foetal bovine serum (FBS) (PAA, Pasching, Austria),
100U/mL penicillin-streptomycin (PAA), 2.5µg/mL fungi-
zone (Sigma), and 100µg/mL gentamycin (Biochrom AG,
Berlin, Germany). Tumour samples were kept on ice until
processed further.
2.2. Establishment of Xenograft Tumour Models in SCID/Beige
Mice. Human tumour samples with an average size of 1cm3
were cut into 2 × 2mm pieces in the presence of digestion
medium (PBS/2mg/mL collagenase III; 37◦C; Worthington
Biochemical Corporation, NJ, USA), transferred into 15mL
tubes (Sarstedt, Wiener Neustadt, Austria) and further
incubated for 1 hour at 37◦C with continuous shaking at 320
cycles per minute (Thermoshaker HTMR 132; Haep Labor
Consult, Bovenden, Germany). To stop digestion, an equal
volume of culture medium (DMEM/10% FBS/50U/mL
penicillin-streptomycin) was added. The obtained single
cell suspension was centrifuged at 180xg for 5 minutes,
and cells were washed twice with PBS. The cell pellet
was resuspended in 1mL of injection medium (RPMI
1640 phenol red free/1% penicillin-streptomycin) and 150-
200µL thereof were inoculated subcutaneously into the
left ﬂank of 3 SCID/beige mice (C.B-17/IcrHsd-Prkcdscid
Lystbg; Harlan-Winkelmann, Borchen, Germany) which had
been anaesthetised by intraperitoneal injection of ketamine
(1mg/10g body weight) and xylazin (0.039mg/10g body
weight). For individual identiﬁcation, microchip transpon-
ders (BackHome; Virbac, Wien, Austria) were implanted
subcutaneously. Animals were kept under speciﬁc pathogen-
free conditions in negative pressure containments (Scant-
ainers, Scanbur, Denmark) with unlimited access to food
and autoclaved tap water. Subcutaneous tumour volume
was estimated according to Carlsson’s formula [16]. Hence,
the largest (a) and smallest (b) superﬁcial diameters of the
tumour were determined once a week using a sliding calliper,
andthenthevolume(V)wascalculated(V = a×b×b/2).At
300–500mm3, tumours were excised and parts of them, that
is, pieces of 2mm3, transplanted into new animals, ﬁxed in
formalinorfrozeninliquidnitrogen.Allanimalexperiments
wereperformedaccordingtoAustrianlawsgoverninganimal
experimentation (GZ 68.205/30-Pr/4/2002; GZ 68.205/59-
BrGT/2004).
2.3. Establishment and Characterisation of Primary and Xeno-
graft Tumour Derived Cell Cultures. Tumour pieces either
obtained from primary (AKH23, KFJ18) or xenografted
tumours (AKH10, KFJ6, KFJ9, KFJ10) were processed as
described above, and obtained single cell suspensions were
transferred into cell culture ﬂasks (Sarstedt) containing
culture medium. Established cell cultures were charac-
terised by immunocytochemistry using antibodies reacting
with human and mouse major histocompatibility complex
(MHC) class I antigens. Brieﬂy, cells were incubated with a
R-phycoerythrin—conjugated mouse anti-human leukocyte
antigen (HLA)-A,B,C (BD Pharmingen, Schwechat, Austria)
or a ﬂuorescein isothiocyanate (FITC)—conjugated mouse
antimouse H-2Dd monoclonal antibody (Becton Dickinson,
Heidelberg, Germany) for one hour at 4◦C in the dark.
Cells were washed twice, resuspended in PBS, and sub-
jected to FACS analysis (FACScalibur, Becton Dickinson).
In addition, cells were stained with an antibody directed
against a human epithelial-speciﬁc antigen (ESA; Serotec,
D¨ usseldorf, Germany) followed by detection with FITC-
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(DakoCytomation, Glostrup, Denmark). After characterisa-
tion, cells usually with passage numbers 5–10 were frozen
in liquid nitrogen for long-term storage. On demand cells
were thawed and expanded for further in vitro analysis
or retransplantation into immunodeﬁcient mice. Therefore,
1–5×106 cells were injected subcutaneously into SCID/beige
mice as described above. In addition to tumour growth in
vivo, anchorage independent growth of recultivated tumour-
derived cells was analysed by colony formation in a standard
soft agar assay [17].
2.4. Histopathological Analysis and Immunohistochemistry.
Xenograft tumours after the ﬁrst or second passage in
mice were excised and ﬁxed in 4% buﬀered formalin
(pH 7.0, Sigma-Aldrich) and embedded in paraﬃn( H i s t o -
Comp, Sanova, Wien, Austria) using automatic embedding
equipment (Tissue Tek, Miles Scientiﬁc, Inc., Ill, USA).
Three µm thick sections of primary and xenograft tumours
were routinely stained with haematoxylin and eosin and
microscopically analysed. To characterise primary tumours
and corresponding xenografts by immunohistochemistry,
the following primary antibodies were used: rabbit poly-
clonal antibody speciﬁc for carcinoembryonic antigen (CEA,
CD66e Ab-2, neat, Labvision Neomarkers, Cheshire, UK),
mouse monoclonal antibodies speciﬁc for cytokeratin 8/18
(CK8/18 Labvision Neomarkers, 1:100 diluted in PBS) and
cytokeratin 20 (CK20, DakoCytomation; 1:50 diluted in
PBS). For detection of CK8/18, sections were digested with
0.1% protease (Sigma-Aldrich) in PBS for 15 minutes.
CK20 was detected after pretreatment with 0.1% proteinase
K (Sigma-Aldrich) in PBS. Sections were then incubated
with 1.5% goat serum (DakoCytomation) for 30 minutes
followed by overnight incubation with the primary antibody
at 4◦C. Detection was performed using the Vectastain
ABC-AP kit (Vector Laboratories, England, UK) with New
Fuchsin (DakoCytomation) as a substrate followed by coun-
terstaining with Mayer’s haemalum (VWR International
GmbH, Dresden, Germany). Sections were covered with
Aquatex (Merck, Darmstadt, Germany) and examined by
light microscopy (Zeiss Axiovert 200M, Carl Zeiss GmbH,
Oberkochen, Germany).
2.5. RNA Extraction, Reverse Transcription, and Quantitative
RT-PCR. RNA was extractedfromtrypsinised cells orfrozen
and pulverised tumour samples according to the RNeasy
Mini Kit protocol (Qiagen, Wien, Austria) and treated
afterwardswithTurboDNase(Ambion,Tex,USA)according
to the manufacturer’s instructions. Subsequently, 150ng
of total RNA were reverse transcribed using the iScript
cDNA synthesis Kit (Bio-Rad Laboratories, Calif, USA).
50µL of cDNA template (105ng total input RNA) were
ampliﬁed using a master mix containing 1x reaction buﬀer
B (Solis Biodyne, Tartu, Estonia), 5mM MgCl2,0 . 2m Mo f
each dNTP (Applied Biosystems, Calif, USA), 300nM ROX
reference dye (Invitrogen, Lofer, Germany) and 1 unit of
hot start Firepol polymerase (Solis Biodyne, Tartu, Estonia)
on TaqMan low density arrays (Applied Biosystems) using
the ABI PRISM 7900HT sequence detection system (Applied
Biosystems). The respective human-speciﬁc real-time PCR
primers and probes are listed in Table 1. According to data
base comparisons (Applied Biosystems), these sequences are
not supposed to cross-react with mouse. Cycling conditions
were as follows: 2 minutes at 50◦C, 10 minutes at 94.5
followed by 40 cycles of 30 seconds at 97◦C and 1 minute
at 59.7◦C. Ct values were determined using the passive
reference dye and manual baseline and threshold settings
in the SDS 2.2 software (Applied Biosystems). Assays with
Ct values above 33 were excluded from analysis due to
variations or inappropriate ampliﬁcation in duplicate wells.
Tumour-derived RNA was tested in duplicates on three
diﬀerent plates, and their mean values were calculated for
further analysis. A calibrator sample consisting of a universal
reference RNA isolated from 10 diﬀerent human cancer
cell lines (Stratagene, Calif, USA) served as an internal
standard for comparison of diﬀerent assays. Diﬀerences in
gene expression levels of each tumour sample were ﬁrst
normalised to the calibrator sample followed by calculation
of diﬀerences between original and xenograft tumours
according to the 2−ΔΔCt method [18]. Normalisation of
real-time RT-PCR data was performed using the geometric
mean (normalisation factor) of the included endogenous
reference genes GUSB (ß-glucuronidase), ACTB (ß-actin)
and rRNA18S (18S ribosomal RNA) within the macros-
based program qBase (http://medgen.ugent.be/qbase).
2.6. Statistical Analysis. To identify genes expressed diﬀer-
entially in all xenografts and parental tumours analysed, a
Wilcoxon paired-samples test was performed (SPSS for Win-
dowsVs.11.5).StatisticalsigniﬁcancewasdeﬁnedasP < .05.
For the analysis of individual original/xenograft tumour
pairs, we considered genes to be diﬀerentially expressed
showingaminimumof2.5-folddiﬀerencebetweenxenograft
and original tumours.
3. Results
3.1. Successful Establishment of Secondary Liver Tumour
Models in SCID/Bg Mice. Human secondary liver tumour
tissue was obtained from patients at the time of surgery or
resection of the neoplasm. In total, tumour samples from 17
patients including liver metastases of colorectal carcinomas
(n = 10), intrahepatic cholangiocellular carcinomas (n =
6) as well as a metastasis of a pancreatic carcinoma were
collected. The tumour tissue was digested with collage-
nase to obtain single cell suspensions which were injected
subcutaneously into SCID/beige mice. Finally, injection of
single cells prepared from 10 diﬀerent samples consisting
of liver metastases originating from colorectal (n = 6),
cholangiocellular (n = 3), and a pancreatic adenocarcinoma
resulted in tumour formation. The main characteristics of
the original xenografted tumour samples are summarised in
Table 2.
3.2. Histopathological Features of Original Human Tumours
Are Conserved in Corresponding Xenografts. In order to
compare original and xenograft tumours morphologically,4 Journal of Biomedicine and Biotechnology
Original tumour
(a)
Xenograft tumour
(b)
(c) (d)
(e) (f)
Figure 1: Histological analysis of original and corresponding xenograft tumours. (a) KFJ6 (colorectal liver metastasis) original tumour, (b)
KFJ6-derived xenograft tumour, (c) AKH10 (cholangiocellular carcinoma) original tumour, (d) AKH10-derived xenograft tumour, (e)
AKH23 (pancreatic adenocarcinoma-derived liver metastasis) original tumour, (f) AKH23-derived xenograft tumour. Sections were stained
with haematoxylin and eosin. Magniﬁcation: 200x.
sectionswerestainedwithhaematoxylin/eosinandexamined
by light microscopy. Representatively for colorectal liver
metastases, sections of the original tumour KFJ6 and its
derived xenograft are shown (see Figures 1(a) and 1(b)).
Both original as well as the xenograft tumours revealed
irregular tubular structures typical for colon adenocarcino-
mas. In most of the established xenograft tumours, large
areas of necrosis were observed (data not shown). The
tumour AKH10 is depicted as an example of an intrahepatic
cholangiocellular carcinoma (see Figures 1(c) and 1(d)).
Pathohistologically, both xenograft and the parental tumour
can be described as a moderately diﬀerentiated adeno-
carcinoma with comparable simple tubular to glandular
structures.Examination ofthelivermetastasisAKH23whichJournal of Biomedicine and Biotechnology 5
Table 1: Sequences ampliﬁed on TaqMan low density arrays.
Gene Gene name Classiﬁcation TaqMan assay IDa
BCL2 B-cell CLL/lymphoma 2 Inhibition of apoptosis Hs00153350 m1
CCND1 Cyclin D1 Kinase activator, cell cycle control, proliferation Hs00277039 m1
CDC25B Cell division cycle 25B Protein phosphatase, cell proliferation Hs00244740 m1
CDKN1B Cyclin-dependent kinase inhibitor 1B (p27,
Kip1) Cell cycle control, tumour suppressor Hs00153277 m1
CTNNB1 Catenin (cadherin-associated protein), beta 1,
88 kDa Cytoskeletal protein, cell adhesion, oncogenesis Hs00170025 m1
EGFR
Epidermal growth factor receptor
(erythroblastic leukemia viral (v-erb-b)
oncogene homolog)
Cell cycle control, proliferation, oncogenesis Hs00193306 m1
ERBB2 v-erb-b2 erythroblastic leukemia viral
oncogene homolog 2
Protein kinase receptor, oncogenesis, cell cycle
control
Hs00170433 m1
ETV4 ets variant gene 4 (E1A enhancer binding
protein, E1AF) Transcription factor, oncogenesis, cell motility Hs00385910 m1
IL6 Interleukin 6 (interferon, beta 2) Chemokine, inhibition of apoptosis Hs00174131 m1
IL6R Interleukin 6 receptor Cell proliferation, immunity and defense Hs00169842 m1
IL8 Interleukin 8 Angiogenesis, cell proliferation/diﬀerentiation Hs00174103 m1
KRAS v-Ki-ras2 Kirsten rat sarcoma 2 viral oncogene
homolog Small GTPase, cell proliferation/diﬀerentiation Hs00270666 m1
MET Met proto-oncogene (hepatocyte growth factor
receptor) Protein kinase receptor, oncogenesis Hs00179845 m1
MMP1 Matrix metalloproteinase 1 (interstitial
collagenase)
Metalloprotease, extracellular matrix break
down
Hs00233958 m1
MMP11 Matrix metalloproteinase 11 (stromelysin 3) Metalloprotease, inhibition of apoptosis Hs00171829 m1
MYC v-myc myelocytomatosis viral oncogene
homolog Oncogene, cell cycle control Hs00153408 m1
PTGS2
Prostaglandin-endoperoxide synthase 2
(prostaglandin G/H synthase and
cyclooxygenase, Cox-2)
Oxidoreductase, lipid metabolism, deregulated
in epithelial tumours
Hs00153133 m1
SERPINB5 Serine proteinase inhibitor, clade B
(ovalbumin), member 5 Proteinase inhibitor, oncogenesis Hs00184728 m1
VEGFA Vascular endothelial growth factor Growth factor, angiogenesis Hs00173626 m1
VEGFC Vascular endothelial growth factor C Cell proliferation and diﬀerentiation Hs00153458 m1
WNT1 Wingless-type MMTV integration site family,
member 1 Signalling molecule, oncogenesis Hs00180529 m1
rRNA18Sb 18S ribosomal RNA Eukaryotic ribosomal RNA gene, obligatory
control
4342379-18S
GUSBb Glucuronidase, beta Galactosidase, carbohydrate metabolism Hs99999908 m1
ACTBb Actin, beta Cytoskeletal protein Hs99999903 m1
a m1 indicates that the TaqMan minor groove binding probe spans an exon junction and will not detect genomic DNA;
bendogenous control genes shown in a pilot study (TaqMan human endogenous control plate) to be equally expressed in all samples investigated.
had originated from a pancreatic adenocarcinoma revealed a
solid undiﬀerentiated large cell carcinoma (see Figure 1(e)).
Tumour cells exhibited anaplastic nuclei and varying
amounts of eosinophilic, particular foamy cytoplasm. Con-
sistently, subcutaneous implantation of cells derived from
tumour AKH23 led to formation of a poorly diﬀerentiated
fast growing anaplastic carcinoma (see Figure 1(f)).
3.3. Typical Tumour Markers Are Equally Expressed in Corre-
sponding Tumour Samples. To further characterise the estab-
lished xenograft tumours and their corresponding original
counterparts, immunohistological stainings for detection of
CEA were performed. CEA is a glycoprotein expressed in
adenocarcinomasoftheintestinaltractandinothertumours
of epithelial origin such as lung adenocarcinoma, pancreatic
adenocarcinoma, and cholangiocellular carcinomas (CCCs)
[19]. Additionally, tumours were stained with antibodies
speciﬁc for CK8/18, which is expressed in simple and glan-
dular epithelia, and CK20, which is primarily expressed in
colon adenocarcinomas. Pancreatic tumours and CCCs may
also express CK20 [20]. As summarised in Table 3,i m m u n o -
histologicalanalysesrevealedsimilarstainingpatternswithin6 Journal of Biomedicine and Biotechnology
Table 2: Relevant characteristics of original human tumour samples.
Tumour ID Age Sex Diagnosisa
AKH10 72 m Intrahepatic multifocal CCC
AKH23 65 f Pancreatic adenocarcinoma derived liver metastasis
AKH47 63 m Intrahepatic CCC
KFJ6 75 m CRC derived liver metastasis
KFJ9 55 f Intrahepatic metastatic CCC
KFJ10 65 f CRC derived liver metastasis
KFJ12 78 m CRC derived liver metastasis
KFJ18 64 f CRC derived liver metastasis
KFJ21 52 m CRC derived liver metastasis
KFJ25 73 m CRC derived liver metastasis
a CCC: cholangiocellular carcinoma; CRC: colorectal carcinoma.
original and xenograft tumour samples with regard to
expression of CEA, CK8/18, and CK20. Positive staining
exclusively detected in distinct original tumour samples
was due to reactions with normal liver cells no more
present in the xenograft tumours. Representative analyses
of original tumours and their corresponding xenografts are
shown in Figures 2–4. Immunohistological comparison of
the original and xenograft tumour KFJ6 in both samples
revealedexpressionofCEAinthecytoplasmandmembranes
of luminal cells (see Figures 2(a) and 2(b)). Additionally,
expression of CK8/18 (see Figures 2(c) and 2(d)) and CK20
(see Figures 2(e) and 2(f)) was detected. AKH10 original
and xenograft tumours (see Figure 3)b o t hr e a c t e dw i t h
antibodies speciﬁc for CEA (see Figures 3(a) and 3(b))
and CK8/18 (see Figures 3(c) and 3(d)) but did not show
expression of CK20 (see Figures 3(e) and 3(f)). The original
pancreatic adenocarcinoma-derived liver metastasis AKH23
(see Figure 4) revealed single cells expressing CEA (see
Figure 4(a)), whereas the corresponding xenograft tumour
appeared negative for CEA expression. A robust staining
in both samples was obtained when expression of CK8/18
(see Figures 4(c) and 4(d)) was analysed. In contrast,
neither original nor xenograft tumour-derived sections
revealed expression of CK20 (see Figures 4(e) and 4(f)).
Based on these ﬁndings, we conclude that the investigated
human tumours retained their typical morphological and
histological characteristics after xenotransplantation into
mice.
3.4. Expression of Cancer Relevant Genes Appears Unaltered
in Xenograft Compared to Original Tumours. In order to
compare the established xenograft tumour models with the
respective original tumour counterparts on a molecular
basis, gene expression analyses were performed. For this
purpose, relative expression levels of a number of cancer-
relevantgenes(seeTable 1)weredeterminedintherespective
corresponding tumour samples using TaqMan low density
expression arrays. Interassay speciﬁc diﬀerences were ﬁrst
normalised to an arbitrarily chosen calibrator (reference
RNA), and then the ratio of gene expression levels in an
original tumour versus the corresponding xenograft tumour
was determined. Genes were considered to be diﬀerentially
expressed when a 2.5-fold minimal diﬀerence between
originalandxenografttumoursampleswasobtained.Table 4
summarises data acquired for a representative selection of
diﬀerent original tumours in comparison to their respective
xenografts. Interestingly, genes encoding cell cycle regulators
and proto-oncogenes, such as Bcl-2, cyclin D1, CDC25B,
cyclin-dependent kinase inhibitor 1B, Erb-b2, K-ras, Met
and Myc as well as epidermal growth factor receptor
(EGFR) and a ß-catenin encoding gene (CTNNB1), showed
comparable expression levels in all the investigated original
and xenograft tumours. Expression of the proto-oncogene
Wnt-1 was neither detected in original nor in xenograft
tumour tissue. In contrast, genes encoding cytokines such
as interleukin 8 (IL-8) and 6 (IL-6), its receptor IL6-R,
cyclooxygenase (Cox)-2, vascular endothelial growth factor
(VEGF)-C as well as matrix metalloproteinase (MMP) 11
appeared to be diﬀerentially expressed in some of the
analysed samples (see Table 4). In particular, IL-6, Cox-2,
and VEGF-C expression was nearly exclusively detected in
original tumour samples. Expression of IL-6 receptor (IL-
6R) was either found to be equal in original and xenograft
tumours or signiﬁcantly increased (4- to 18-fold) in some of
the original tumours (AKH10, KFJ18, KFJ21). Similarly, IL-
8 appeared to be 12- to 100-fold higher expressed in original
tumour samples compared to the corresponding xenograft
tissue. Analysis of MMP-11 expression revealed a 4- to 22-
fold diﬀerence between original and xenograft tumours.
Although few more diﬀerenceswere encountered concerning
expression of serpin and VEGF (AKH23), statistical analysis
of results obtained for all investigated original and xenograft
tumour samples revealed signiﬁcant diﬀerences exclu-
sively for the expression of IL-8 (P = .017) and MMP-11
(P = .018).
Finally, gene expression levels of original and xenograft
tumour samples exemplarily were compared to those of
their derived cell cultures (see Table 5). Immunocytochem-
ical characterisation of established cell cultures conﬁrmed
their human and epithelial origin, respectively (data not
shown). Again, the most striking diﬀerences in expres-
sion levels were observed for IL6-R and MMP encoding
genes. IL6R-expression levels were about 5-fold decreased in
tumour-derived cell cultures compared to the corresponding
tissue. Demonstrative diﬀerences in MMP-1 expression
were observed for AKH23-derived cells, which showedJournal of Biomedicine and Biotechnology 7
Table 3:Immunohistochemicalanalysesofhumanoriginalandcorrespondingxenografttumours.CCC:cholangiocellularcarcinoma;CRC:
colorectal carcinoma; n.a.: not analysed; −: no staining; +: positive staining; bsingle stained cells or staining restricted to normal liver cells;
orig.: original tumour sample; xeno.: xenograft tumour sample.
Tumour Diagnosis CEA orig./xeno. CK8/18 orig./xeno. CK20 orig./xeno.
AKH10 Intrahepatic metastatic CCC +/+ +/+ −/−
AKH23 Liver metastasis of pancreatic cancer +b/− +/+ −/−
AKH47 Intrahepatic CCC +b/− +/+ −/−
KFJ6 CRC liver metastasis +/+ +/+ +/+
KFJ9 Intrahepatic metastatic CCC +/+ +/+ +/+
KFJ10 CRC liver metastasis +/+ +/+ +/+
KFJ12 CRC liver metastasis +/+ +/+ +/+
KFJ18 CRC liver metastasis +/+ +/+ +/+
KFJ21 CRC liver metastasis +/+ +/+ +/+
KFJ25 CRC liver metastasis +/+ +/+ +/+
Table 4: Relative diﬀerences in gene expression levels (n-fold) of original tumour samples compared to the corresponding xenograft
tumour. Indicated values represent the mean of three measurements including the calculated standard deviation. Ratios were calculated
after normalisation of individual RNA amounts to a standard reference RNA. Values indicating diﬀerences higher than 2.5-fold are printed
in bold. Gene symbols correspond with Table 1. n.d.: not determinable, Ct values obtained with cDNA derived either from the xenograft (#)
or from both tumour samples were below threshold (>39).
AKH10 AKH23 KFJ6 KFJ9 KFJ10 KFJ12 KFJ18 KFJ21
BCL2 0.35 ± 0.06 1.97 ±0.46 1.66 ±0.72 0.37 ± 0.09 0.80 ±0.20 0.71 ±0.08 1.10 ±0.26 0.52 ±0.03
CCND1 0.53 ±0.02 1.91 ±0.25 1.05 ±0.09 0.94 ±0.22 0.79 ±0.04 1.96 ±0.09 0.64 ±0.05 0.74 ±0.15
CDC25B 1.79 ±0.31 2.70 ± 0.44 0.45 ±0.02 0.51 ±0.04 1.05 ±0.11 0.66 ±0.12 0.60 ±0.01 0.68 ±0.12
CDKN1B 1.93 ±0.65 1.01 ±0.08 0.85 ±0.07 1.47 ±0.12 2.03 ±0.32 0.82 ±0.13 0.66 ±0.16 0.94 ±0.14
CTNNB1 2.08 ±0.91 1.20 ±0.24 0.85 ±0.11 1.75 ±0.02 1.38 ±0.11 0.82 ±0.23 0.86 ±0.19 0.86 ±0.15
EGFR 0.72 ±0.21 .05 ±0.10 .75 ±0.08 0.75 ±0.08 1.01 ±0.12 0.64 ±0.12 1.02 ±0.17 1.00 ±0.22
ERBB2 0.97 ±0.21 1.43 ±0.15 0.88 ±0.05 1.04 ±0.03 0.82 ±0.16 0.74 ±0.08 0.58 ±0.02 1.21 ±0.46
ETV4 1.79 ±0.17 1.41 ±0.27 0.67 ±0.05 0.92 ±0.11 1.02 ±0.11 0.45 ±0.14 0.49 ±0.12 0.98 ±0.13
IL6 1.69 ±0.55 0.26 ± 0.04 n.d.# 0.30 ± 0.04 n.d.# n.d.# n.d.# n.d.#
IL6R 4.86 ± 1.35 0.99 ±0.09 n.d.# 0.75 ±0.05 1.75 ±0.14 0.73 ±0.12 18.33 ± 1.98 4.41 ± 0.3
IL8 1.06 ±0.28 2.65 ± 1.0 18.46 ± 5.67 12.81 ± 3.43 23.46 ± 6.74 19.39 ± 4.43 34.84 ± 3.42 112.68 ± 23.33
KRAS2 0.97 ±0.23 1.13 ±0.14 0.81 ±0.14 0.85 ±0.10 1.62 ±0.37 0.78 ±0.06 0.87 ±0.10 0.79 ±0.18
MET 0.58 ±0.14 1.61 ±0.25 0.57 ±0.08 2.35 ±0.16 0.95 ±0.04 0.69 ±0.01 0.58 ±0.10 0.81 ±0.14
MMP1 0.65 ±0.08 n.d.# 0.97 ±0.38 n.d. 0.57 ±0.36 n.d. 0.95 ±0.13 n.d.#
MMP11 15.62 ± 6.10 22.13 ± 5.08 5.66 ± 0.21 n.d.# 8.33 ± 1.68 3.98 ± 1.24 13.72 ± 2.43 10.88 ± 0.42
MYC 0.60 ±0.08 1.60 ±0.46 0.89 ±0.11 0.89 ±0.18 0.90 ±0.03 0.86 ±0.25 0.66 ±0.03 0.97 ±0.05
PTGS2 0.83 ±0.18 0.43 ±0.07 n.d.# n.d.# n.d.# n.d.# n.d.# n.d.#
SERPINB5 n.d. 17.66 ± 4.92 1.11 ±0.15 1.26 ±0.10 0.58 ±0.18 1.12 ±0.36 0.38 ± 0.05 1.46 ±0.08
VEGFA 1.48 ±0.23 0.17 ± 0.01 1.09 ±0.04 2.78 ± 0.32 2.11 ±0.23 0.94 ±0.12 0.91 ±0.08 1.38 ±0.22
VEGFC 1.52 ±0.32 n.d.# n.d.# n.d.# n.d.# n.d.# n.d.# n.d.#
WNT1 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
a >300-fold higher amount of mRNA compared to the
parental tumour. In contrast, MMP-11 (10-fold) and VEGF
(4-fold) expression levels were found to be higher in AKH23
original tumour tissue.
4. Discussion
T u m o u rm o u s em o d e l sa sw e l la st u m o u r - d e r i v e dc e l ll i n e s
are a prerequisite for the development and evaluation of
new and existing tumour therapies. Although a number
of xenograft models have been published for colorectal
carcinomas and pancreatic adenocarcinomas in most cases,
these were established from cultured cell lines available for
example from ATCC. In these examples, it is not clear how
long-term cultivation of these (mostly poorly characterised)
cells aﬀects tumour formation and biology. Therefore, we
decidedtoestablishxenograftsdirectlyfrompatienttumours
and subsequently analyse both tissues in detail to demon-
strate that the generated model closely reﬂects the original8 Journal of Biomedicine and Biotechnology
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Figure 2: Immunohistochemical analysis of original and corresponding xenograft tumour KFJ6. Sections were stained with (a), (b) antibodies
speciﬁc for CEA, (c), (d) cytokeratin 8/18, and (e), (f) cytokeratin 20. Magniﬁcation: 200x.
malignancy.Inthepresentstudy,wereporttheestablishment
and detailed characterisation of human xenograft tumour
models derived from secondary liver cancer, that is, tumour
metastases originating from colorectal, cholangiocellular,
and pancreatic cancers. Xenografts were established directly
from tumour biopsies omitting culturing of isolated cells,
which may cause development of tumours that do not
share the characteristics of the respective original due to
the selection and expansion of speciﬁc cell clones. The
applied method of enzymatic digestion of whole tumour
samples followed by injection of a mixture of tumour and
stromal cells was shown to overcome this obstacle. With
respect to xenografts derived from colorectal carcinomas, the
applied method resulted in a take rate of 60% and 50%,
respectively, when cholangiocellular carcinoma-derived cells
were injected. Retrospective analysis of xenograft tumour
growth with clinical data of the respective patient did not
reveal any signiﬁcant correlation. Instead, the condition ofJournal of Biomedicine and Biotechnology 9
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Figure 3:ImmunohistochemicalanalysisoforiginalandcorrespondingxenografttumourAKH10.Sectionswerestainedwith(a),(b)antibodies
speciﬁc for CEA, (c), (d) cytokeratin 8/18, and (e), (f) cytokeratin 20. Magniﬁcation: 200x.
the primary tumour sample, for example, the presence of
large necrotic areas appeared to be critical.
Pathohistological examination of the established xeno-
grafts and comparison to their respective original tumours
demonstrated that the typical morphology of the tumours
was retained after xenotransplantation. Moreover, immuno-
histological analyses showed that each of the established
xenograft tumours retained the typical tumour-speciﬁc
antigen proﬁle observed in the original tumour sample.
Cell cultures established either from original or xenograft
tumour tissues were shown to be of epithelial origin and not
contaminated with murine cells (data not shown). Although
the respective tumour transplants could be passaged in mice
for extended periods (up to 30 times) without major changes
in growth behaviour and morphology (data not shown),
a cryoconservation protocol was established facilitating
storage of samples at early passages to avoid development
of histopathological alterations over time. Retransplanta-
tion experiments with tumour samples frozen for diﬀerent
time spans (3, 6, and 12 months) revealed an average
take rate of 70% to 100% in both SCID/beige and nude
mice.
Molecular characterisation based on quantitative gene
expressionanalysesusinghumanspeciﬁcprimersandprobes10 Journal of Biomedicine and Biotechnology
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Figure 4:ImmunohistochemicalanalysisoforiginalandcorrespondingxenografttumourAKH23.Sectionswerestainedwith(a),(b)antibodies
speciﬁc for CEA, (c), (d) cytokeratin 8/18, and (e), (f) cytokeratin 20. (a) Arrows indicate few stained cells in the original tumour AKH23
reacting with the CEA-speciﬁc antibody. Magniﬁcation: 200x.
revealed that in most of the corresponding original and
xenograft tumour samples expression of oncogenes and
genes involved in cell cycle regulation appeared not to
be aﬀected by the xenografting process. Major diﬀerences
withinoriginalandxenografttumoursamplesaswellastheir
derived cell cultures were detected regarding genes encoding
cytokines (IL-8, IL-6) and matrix metalloproteinases (MMP-
1, MMP-11). This ﬁnding can be explained by the fact
that these molecules are rather expressed by inﬂammatory
cells (monocytes, neutrophils), stromal ﬁbroblasts, and
endothelial cells than by the tumour cells themselves. A high
level IL-8 expression, however, was also reported in culturedJournal of Biomedicine and Biotechnology 11
Table 5: Relative diﬀerences in gene expression levels (n-fold) within tumour samples compared to derived cell cultures. n.d.: not
determinable, Ct values obtained with cDNA derived either from cultured cells ($) or from both tumour samples and cells were below
threshold (>39).
AKH23 original cells KFJ9 xenograft cells KFJ10 xenograft cells
BCL2 0.37 ± 0.03 2.60 ± 0.64 35.13 ± 7.76
CCND1 0.40 ±0.09 0.85 ± 0.33 0.50 ±0.08
CDC25B 0.89 ±0.14 1.18 ± 0.11 0.50 ±0.08
CDKN1B 0.90 ±0.17 0.55 ± 0.11 0.74 ±0.13
CTNNB1 0.54 ±0.12 0.93 ±0.21 .03 ±0.08
EGFR 0.46 ±0.12 0.36 ± 0.09 0.78 ±0.07
ERBB2 0.73 ±0.16 1.24 ± 0.15 0.68 ± 0.1
ETV4 0.78 ±0.17 0.51 ± 0.12 1.21 ±0.16
IL6 n.d.$ 0.61 ± 0.15 n.d.$
IL6R 5.88 ± 1.02 4.47 ± 0.65 2.27 ±0.33
IL8 0.54 ±0.08 0.89 ± 0.41 0.92 ±0.03
KRAS2 1.08 ±0.16 0.50 ± 0.11 0.73 ±0.24
MET 0.49 ±0.11 0.32 ± 0.07 0.42 ±0.06
MMP1 0.0027 ± 0.0006 n.d. 1.06 ±0.37
MMP11 10.47 ± 0.99 n.d.$ 1.41 ±0.38
MYC 0.87 ±0.08 0.53 ± 0.13 0.37 ± 0.05
PTGS2 0.71 ±0.22 n.d. n.d.
SERPINB5 0.91 ±0.21 0.80 ± 0.18 0.43 ±0.04
VEGFA 4.50 ± 0.92 0.96 ± 0.17 1.83 ±0.21
VEGFC n.d.$ n.d. n.d.
WNT1 n.d. n.d. n.d.
colon carcinoma cells, where it was associated with the
metastaticbehaviourofthesecells[21].Consistently,wehave
shown IL-8 expression in cultured xenograft-derived colon
carcinoma cells (e.g., KFJ10), and their metastatic potential
was demonstrated by colony formation in soft agar assays
(data not shown).
Matrix metalloproteinases (MMPs) are a family of
extracellular matrix degrading enzymes, which have their
physiological role in tissue remodelling processes such as
embryonic development or wound healing [22]. In cancer,
MMPs are described to be involved in tumour invasion,
metastasis, and angiogenesis [23,24].MMP-1,alsoknown as
interstitial collagenase, is expressed in a wide variety of cells
such as stromal ﬁbroblasts, endothelial cells, macrophages,
and epithelial cells [25]. Either equal expression levels were
found in original and xenograft tumours or expression
was exclusively detected in original tumours. A weak or
lacking MMP-1 expression in some of the xenograft tumours
could not be linked to an individual tumour type. Orig-
inal tumours representing liver metastases showed higher
MMP-1 levels, reﬂecting the potential of tumour cells to
invade and metastasise from their original site to distant
organs [26]. Accordingly, AKH23 primary tumour-derived
cells exhibiting a markedly high MMP-1 expression level
demonstrated a very aggressive growth behaviour when
injected into immunodeﬁcient mice. Injection of 5 × 106
cells in this case resulted in growth of tumours of up to
1000mm3 within 35 days whereas in average xenografted
cellstook60to80daystoreachthistumourvolume(datanot
shown). MMP-11 in comparison to MMP-1 is described to
be speciﬁcally expressed in stromal ﬁbroblasts surrounding
tumour cells [27]. Thus, the determined reduced expression
level of MMP-11 in xenograft tumours most probably is
due to the absence of human stroma cells in the murine
environment. Interestingly, expression of Cox-2 (PTGS2)
and VEGF-C, both known to regulate angiogenesis and
lymphangiogenesis, was detected in original tumour samples
but, in contrast to VEGF-A, was beyond detection limits in
most of the xenograft tissues. Recently, it has been described
thatthesetwogenesarecoexpressedinhumancolorectalcar-
cinoma cells and can be signiﬁcantly associated with lymph
node metastasis and prognosis [28]. Further investigation
of the mechanisms of down regulation of expression of
lymphangiogenesis inducing factors in xenografted tumours
may give insight into metastatic progression of CRC.
5. Conclusion
The developed carefully characterised human xenograft
tumours derived from secondary liver tumours share
assertive characteristics with their respective original human
counterparts. In addition, the established cell cultures oﬀer
the possibility to evaluate new therapeutic strategies in
vitro before their use in vivo in the corresponding tumour
mouse models. These valuable tools might be used for the
development and preclinical evaluation of new therapeutic
drugs as well as of alternative methods such as expression12 Journal of Biomedicine and Biotechnology
targeted retroviral vectors [29] or liver speciﬁc therapeutic
nanoparticles [30] generated for an application in cancer
gene therapy.
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